About Atantares
Atantares is a company based in Cambridge (United States) founded in 2020 by Xin Zhao, Aniruddh Sarkar, and Kumaran Kolandaivelu. Atantares has raised $13.99 million across 3 funding rounds from investors including Qiming Venture Partners, Alibaba Health and Frees Fund. Atantares operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter Cambridge, United States
- Founders Xin Zhao, Aniruddh Sarkar, Kumaran Kolandaivelu
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$13.99 M (USD)
in 3 rounds
-
Latest Funding Round
$13.99 M (USD), Seed
Jul 31, 2023
-
Investors
Qiming Venture Partners
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Atantares
Atantares has successfully raised a total of $13.99M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $13.99 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Atantares
Atantares has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Qiming Venture Partners, Alibaba Health and Frees Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech focused VC firm investing in early stage companies in the US & China
|
Locked | Locked | Locked | |
|
Venture capital investments are directed toward multiple sectors.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Atantares
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Atantares
Investment portfolio details for Atantares
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Atantares
Detailed financials for Atantares
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Atantares Comparisons
Peer comparison for Atantares
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Atantares
Atantares operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of Atantares
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Atantares
Complete news archive for Atantares
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Atantares
Atantares was founded in 2020.
Atantares is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Xin Zhao is the current CEO of Atantares. They have also founded this company.
Atantares is a funded company, having raised a total of $13.99M across 3 funding rounds to date.
Developer of precision medicines smart diagnostic devices by fusing biochip and AI technologies. The company has developed a coagulation device that helps in monitoring specific drugs or blood products. It uses coagulation assays that monitor platelet function tests, clotting times, and viscoelasticity with a proprietary biochip platform. It provides a chimeric antigen receptor that helps in the treatment of hematological tumors, cardiac diseases, neurological disorders, and cancer. It uses an ultrasensitive immunoassay platform that provides cytokine profile data for managing CAR T-cell therapy and CRS mitigation.
Atantares's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Atantares has 7 investors. Key investors include Qiming Venture Partners, Alibaba Health, Frees Fund, Asia Green Fund, and Fosun Health Capital.